Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofusa-2
NCT05393713Phase 1Terminated
- Sponsor
- Mayo Clinic
- Start
- Oct 2022
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of danburstotug in melanoma, sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose up to 42 days and Incidence of Adverse Events up to 2 years. Started Oct 2022; status: terminated.
02
Drugs
danburstotug
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05393713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393713.